ITCC Loxo Biology Post-doctoral Fellowship Program
ITCC has become the principal European organisation for research and development of new therapeutics for children with cancer, in collaboration with industry, regulatory bodies and parent organisations. This year, Loxo Oncology, Inc. has approved ITCC’s request to support a 2-year biology fellowship undertaking “wet lab” research. The research project should be performed in one of the ITCC-affiliated biology labs, and should foster interaction of at least two ITCC sites.
It is with great pleasure that I can announce that the recipient of the first ITCC Loxo Biology Fellowship is Siebe Loontiens from the University of Ghent. Siebe’s research proposal is “Replication stress checkpoint addiction in neuroblastoma: exploring mechanisms and therapeutic opportunities”. The funding support from Loxo is a very exciting development in the education programme we are promoting within ITCC and we hope more opportunities like this will follow. Can I take this moment to thank all the applicants for submitting their proposals, it was not an easy decision. We will make sure that the ITCC membership are kept up to date with Siebe’s project over the next couple of years.
ITCC Education and Training Committee Chair"
Flims is the way thousands of young professionals and medical students call the most exclusive opportunity to learn the essentials of an oncological clinical trial design in Europe. The annual joint ECCO-AACR-EORTC-ESMO workshop on ‘Methods in Clinical Cancer Research’ takes place every summer in Flims, Switzerland: the access to the workshop is under competition, but this is a highly regarded training opportunity for all junior paediatric haemato-oncologists.
To fulfill its objective to facilitate medical and professional co-operation across Europe, ITCC is keen to provide fellowship opportunities to young oncologists, and on a regular basis we have sponsored the attendance to this highly competitive workshop for one deserving young oncologist, who will develop a clinical trial proposal on childhood cancer.